A canine skin treatment from Zoetis has been named best new product of 2014 in a survey of vets.
It was mentioned by 88 of 300 practising UK vets (29%) as the one product that stood out for them among all new veterinary products introduced last year.
Bravecto by MSD, an antiparasitic chewable treatment lasting up to 12 weeks, came second with 12% of mentions.
Semintra by Boehringer Ingelheim, a product introduced in 2013, was put forward by 10% of vets, placing it in third position. Semintra is a veterinary angiotensin receptor blocker used in cats suffering from chronic kidney disease.
Broadline by Merial, an antiparasitic chewable tablet for cats, was the next product choice, mentioned by 5% of vets.
The survey was conducted online last month (February) using Vetspanel, CM Research’s community of vets. The majority of participants were companion animal vets, with 12% equine, large animal vets or vets treating exotics/wildlife.
The questions were unprompted, ensuring respondents were not influenced by pre-set survey options. As evidence of this, some vets suggested products launched before 2014. Several equine vets considered Vulketan by Elanco to be the best new veterinary product of 2014. Osphos by Dechra was also mentioned by a few equine vets. However, the number of equine vets taking part in the survey was too low to draw definite conclusions.
The survey was expanded to cover France and Germany, with differences found between the three markets. In France, Bravecto was top with 36% of mentions, NexGard by Merial was second with 18% and Broadline third, with 6%. Bravecto also topped the German survey, with 24%. Apoquel was second with 23% and Broadline was third with 8%.